와파린과 생약제의 약물 상호작용 리뷰

키워드

참고문헌 (103)

1. Bent W., "Herbal medicine in the United States: review of efficacy, safety, and regulation-grand rounds at University of California. San Francisco Medical Center", J Gen Intern Med, 23(6), pp.854~859 (2008)
2. Okoro C.A., "Has the use of complementary and alternative medicine therapies by U.S. adults with chronic disease-related functional limitations changed from 2002 to 2007", J Altern Complement Med, 19(3), pp.217~223 (2013)
3. 옥선명, "The Use of Complementary and Alternative Medicine in a General Population in South Korea: Results from a National Survey in 2006", Journal of Korean Medical Science, 24(1), pp.1~6 (2009), 대한의학회
4. Butterweck V., "Potential of pharmacokinetic profiling for detecting herbal interactions with drugs", Clin Pharmacokinet, 47(6), pp.383~397 (2008)
5. Tarirai C., "Herb-drug pharmacokinetic interactions reviewed", Expert Opin Drug Metab Toxicol, 6(12), pp.1515~1538 (2010)
6. Unger M., "Pharmacokinetic drug interactions by herbal drugs: critical evaluation and clinical relevance", Wien Med Wochenschr, 160(21), pp.571~577 (2010)
7. McFadden R., "Interactions between drugs and four common medicinal herbs", Nurs Stand, 25(19), pp.65~68 (2011)
8. Bush T.M., "Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey", Alternat Ther Health Med, 13(2), pp.30~35 (2007)
9. 이수정, "지역약국 방문 만성질환 노인환자의 건강보조식품 복용실태와 처방의약품과의 상호작용 연구", 한국임상약학회지, 22(4), pp.347~355 (2012), 한국임상약학회
10. Hafner-Blumenstiel V., "Herbal drugdrug interaction and adverse drug reactions", Ther Umsch, 68(1), pp.54~57 (2011)
11. Ernst E., "The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava", Ann Intern Med, 136(1), pp.42~53 (2002)
12. Kennedy J., "Patient disclosure about herb and supplement use among adults in the US", Evid Based Complement Alternat Med, 5(4), pp.451~456 (2008)
13. Furie K.L., "Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association", American Stroke Association, 2012, pp.43(1), 3442~3453
14. Anand S.S., "Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Qwave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results", Circulation, 98(11), pp.1064~1070 (1998)
15. Suvarna R., "Possible interaction between warfarin and cranberry juice", BMJ, 327(7429), pp.1454~ (2003)
16. Williamson E.M., "Drug interactions between herbal and prescription medicines", Drug Saf, 26(15), pp.1075~1092 (2003)
17. Yang X.X., "Drug-herb interactions: eliminating toxicity with hard drug design", Curr Pharm, 12, pp.4649~4664 (2006)
18. Venkataramanan R., "In vitro and in vivo assessment of herb drug interactions", Life Sci, 78(18), pp.2105~2015 (2006)
19. Williams P.A., "Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone", Science, 305(5684), pp.683~686 (2004)
20. Pelkonen O., "Inhibition and induction of human cytochrome P450 enzymes: current status", Arch. Toxicol, 82(10), pp.667~715 (2008)
21. Zhou S., "Interaction of herbs with cytochrome P450", Drug Metab Rev, 35(1), pp.35~98 (2003)
22. Zhou S., "Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4", Ther Clin Risk Manag, 1(1), pp.3~13 (2005)
23. Zhou S.F., "Clinically important drug interactions potentially involving mechanism- based inhibition of cytochrome P450 3A4 and the role of therapeutic drugmonitoring", Ther Drug Monit, 29(6), pp.687~710 (2007)
24. Zhou S., "Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4", Curr Drug Metab, 5(5), pp.415~442 (2004)
25. Lin J.H., "CYP induction-mediated drug interactions: in vitro assessment and clinical implications", Pharm Res, 23(6), pp.1089~1116 (2006)
26. Tirona R.G., "Herbal product-drug interactions mediated by induction", Br J Clin Pharmacol, 61(6), pp.677~681 (2006)
27. Jana S., "Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions", Curr Protein Pept Sci, 8(6), pp.619~628 (2007)
28. Whitlock J.P., "Induction of cytochrome P4501A1", Ann Rev Pharmacol Toxicol, 39, pp.103~125 (1999)
29. Wang H., "Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors", Curr Drug Metab, 4(6), pp.515~525 (2003)
30. Kliewer S.A., "The nuclear pregnane X receptor regulates xenobiotic detoxification", J Nutr, 133(7), pp.2444~2447 (2003)
31. Tukey R.H., "Human UDP-glucuronosyltransferases: metabolism, expression, and disease", Ann Rev Pharmacol Toxicol, 40, pp.581~616 (2000)
32. Guillemette C., "Pharmacogenomics of human UDP-glucuronosyltransferase enzymes", Pharmacogenomics J, 3(3), pp.136~158 (2003)
33. Lee H.S., "In vitro metabolism of eupatilin by multiple cytochrome P450 and UDPglucuronosyltransferase enzymes", Xenobiotica, 37(8), pp.803~817 (2007)
34. Hoehle S.I., "Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases", Mol Nutr Food Res, 51(8), pp.932~938 (2007)
35. Ambudkar S.V., "Pglycoprotein: from genomics to mechanism", Oncogene, 22(47), pp.7468~7485 (2003)
36. Sadeque A.J., "Increased drug delivery to the brain by P-glycoprotein inhibition", Clin Pharmacol Ther, 68(3), pp.231~237 (2000)
37. Takano M., "Expression and function of efflux drug transporters in the intestine", Pharmacol Ther, 109(2), pp.137~161 (2006)
38. Mandava N., "Transporter targeted drug delivery", J Drug Del Sci Tech, 20(2), pp.89~99 (2010)
39. Hellum B.H., "In vitro inhibition of CYP3A4 metabolism and Pglycoprotein- mediated transport by trade herbal products", Basic Clin Pharmacol Toxicol, 102(5), pp.466~475 (2008)
40. Breedveld P., "Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs", Trends Pharmacol Sci, 27(1), pp.17~24 (2005)
41. Varma M.V.S., "P-glycoprotein inhibitors and their screening: a per-spective from bioavailability enhancement", Pharmacol Res, 48(4), pp.347~359 (2003)
42. Zhang L., "Scientific perspective on drug transporters and their role in drug interactions", Mol Pharm, 3(6), pp.62~69 (2006)
43. Jiang X., "Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects", Br J Clin Pharmacol, 57(5), pp.592~599 (2004)
44. Jiang X., "Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic- pharmacodynamic modeling approach", J Clin Pharmacol, 46(11), pp.1370~1378 (2006)
45. Li M., "Pungent ginger components modulates human cytochrome P450 enzymes in vitro", Acta Pharmacol Sin, 2013, pp.49~ (2013)[DOI]
46. Kaminsky L.S., "Human P450 metabolism of warfarin", Pharmacol Ther, 73(1), pp.67~74 (1997)
47. Ramsay N.A., "Complementary and alternative medicine use among patients starting warfarin", Br J Haematol, 130(5), pp.777~780 (2005)
48. Taylor J.R., "Probable antagonism of warfarin by green tea", Ann Pharmacother, 33(4), pp.426~428 (1999)
49. Parker D.L., "Interaction between warfarin and black tea", Ann Pharmacother, 43(1), pp.150~151 (2009)
50. O'Hara M., "A review of 12 commonly used medicinal herbs", Arch Fam Med, 7(6), pp.523~536 (1998)
51. Segal R., "Warfarin interaction with Matricaria chamomilla", CMAJ, 174(9), pp.1281~1282 (2006)
52. Newall C., "A guide for health-care professionals, herbal medicines", pp.132~ (1996), Pharmaceutical Press
53. Ganzera M., "Inhibitory effects of the essential oil chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes", Life Sci, 78(8), pp.856~861 (2006)
54. Seifried H.E., "A review of the interaction among dietary antioxidants and reactive oxygen species", J Nutr Biochem, 18(9), pp.567~579 (2007)
55. Halliwell B., "Dietary polyphenols: good, bad, or indifferent for your health", Cardiovasc Res, 73(2), pp.341~347 (2007)
56. Kontiokari T., "Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women", BMJ, 322(7302), pp.1571~ (2001)
57. Mohammed A.M.I., "Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects", Br J Pharmacol, 154(8), pp.1691~1700 (2008)
58. Lilja J.J., "Effects of caily ingestion of cranberry juice on the pharmacokinetics of warfarin, Tizanidine, and Midazolam? Probes of CYP2C9, CYP1A2, and CYP3A4", Clin Pharmacol Ther, 81(6), pp.833~839 (2007)
59. Li Z., "Cranberry does not affect prothrombin time in male subjects on warfarin", J Am Diet Assoc, 106(12), pp.2057~2061 (2006)
60. Rindone J.P., "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding", Am J Ther, 13(3), pp.283~284 (2006)
61. Paeng C. H., "Interaction between warfarin and cranberry juice", Clin Ther, 29, pp.1730~1735 (2007)
62. Hodek P., "Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450", Chem Biol Interact, 139(1), pp.1~21 (2002)
63. Mashour N.H., "Herbal medicines for the treatment of cardiovascular disease: clinical considerations", Arch Intern Med, 158(20), pp.2225~2234 (1998)
64. Cheng T.O., "The international textbook of cardiology", pp.1067~1070 (1987), Pergamon
65. Izzat M.B., "A taste of Chinese medicine", Ann Thorac Surg, 66(3), pp.941~942 (1998)
66. Tam L.S., "Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil", Aust N Z J Med, 25(3), pp.258~ (1995)
67. Yu C.M., "Chinese herbs and warfarin potentiation by 'danshen'", J Intern Med, 241(4), pp.337~339 (1997)
68. Chan K., "The effects of danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats", J Pharm Pharmacol, 47(5), pp.402~406 (1995)
69. Lawrence J.D., "Potentiation of warfarin by dong quai", Pharmacotherapy, 19(7), pp.870~876 (1999)
70. Zhao K.J., "Molecular Genetic and Chemical Assessment of Radix Angelica (Danggui) in China", J Agric Food Chem, 51(9), pp.2576~2583 (2003)
71. Jia M., "Anti-oxidative effect of Angelica polysaccharide sulfate", Zhong Yao Cai, 30(2), pp.185~188 (2007)
72. Janetzky K., "Probable interactions between warfarin and ginseng", Am J Health Syst Pharm, 54(6), pp.692~693 (1997)
73. Rosado M.F., "Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product", Cardiology, 99(2), pp.111~ (2003)
74. Yuan C.S., "Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial", Ann Intern Med, 141(1), pp.23~27 (2004)
75. Lee S.H., "Interaction between warfarin and Panax ginseng in ischemic stroke patients", J Altern Complement Med, 14(6), pp.715~721 (2008)
76. Hsu, H.Y., "Oriental Materia Medica a Concise Guide", Oriental Healing Arts Institute, 544~545 (1986)
77. Reid D.P., "Chinese herbal medicine", pp.153~ (1993), Shambhala Publications
78. Ou M., "Chinese-English manual of common used in traditional Chinese medicine", pp.357~ (1999), Guangdong Science and Technology Publishing House, Joint Publishing (HK)
79. Rivera C.A., "Probable Interaction Between Lycium barbarum (Goji) and Warfarin", Pharmacotherapy, 32(3), pp.50~53 (2012)
80. Lam A.Y., "Possible interaction between warfarin and Lycium barbarum L", Ann Pharmacother, 35(10), pp.1199~1201 (2001)
81. Leung H., "Warfarin overdose due to the possible effects of Lycium barbarum L", Food Chem Toxicol, 46(5), pp.1860~1862 (2008)
82. Heinicke R.M., "The pharmacologically active ingredient of noni", Bull-Pacific Trop Botanical Garden, 15(1), pp.10~14 (1985)
83. Carr M.E., "Coumadin resistance and the vitamin supplement "Noni"", Am J Hematol, 77(1), pp.103~ (2004)
84. Mueller B.A., "Noni juice (Morinda citrifolia): hidden potential for hyperkalemia", Am J Kidney Dis, 35(2), pp.310~312 (2000)
85. Banihani S., "Pomegranate and type 2 diabetes", Nutr Res, 33(5), pp.341~348 (2013)
86. Mirmiran P., "Effect of pomegranate seed oil on hyperlipemic subjects: a double-blind placebo-controlled clinical trial", Br J Nutr, 104(3), pp.402~406 (2010)
87. Ismail T., "Pomegranate peel and fruit extracts: a review of potential anti-inflammatory and anti-infective effects", J Ethnopharmacol, 143(2), pp.397~405 (2012)
88. Komperda K.E., "Potential interaction between pomegranate juice and warfarin", Pharmacotherapy, 29(8), pp.1002~1006 (2009)
89. Hidaka M., "Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity", Drug Metab Dispos, 32(6), pp.581~583 (2004)
90. Hidaka M., "Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats", Drug Metab Dispos, 33(5), pp.644~648 (2005)
91. Kim H., "Inhibitory effects of fruit juices on CYP3A activity", Drug Metab Dispos, 34(4), pp.521~523 (2006)
92. Solomon D., "Potential of St John’s wort for the treatment of depression: the economic perspective", Aust N Z J Psychiatry, 45(2), pp.123~130 (2011)
93. Butterweck V., "St John’s wort: role of active compounds for its mechanism of action and efficacy", Wien Med Wochenschr, 157(13), pp.356~361 (2007)
94. Arold G., "No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract", Planta Med, 71(4), pp.331~337 (2005)
95. Wang Z., "The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity", Clin Pharmacol Ther, 70(4), pp.317~326 (2001)
96. Macan H., "Aged garlic extract may be safe for patients on warfarin therapy", J Nutr, 136(3), pp.793~795 (2006)
97. Greenblatt D.J., "In vitro interactions of water-soluble garlic components with human cytochromes p450", J Nutr, 136(3), pp.806~809 (2006)
98. Ho B.E., "Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes", Sci Pharm, 78(3), pp.473~481 (2010)
99. Weinmann S., "Effects of Ginkgo biloba in dementia: systematic review and meta-analysis", BMC Geriatr, 17, pp.10~ (2010)[DOI]
100. Jiang X., "Effect of Ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects", Br J Clin Pharmacol, 59(4), pp.425~432 (2005)
101. Engelsen J., "Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial", Thromb Haemost, 87(6), pp.1075~1076 (2002)
102. Matthews Jr M.K., "Association of Ginkgo biloba with intracerebral hemorrhage", Neurology, 50(6), pp.1993~1994 (1998)
103. Fessenden J.M., "Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy", Am Surg, 67(1), pp.33~35 (2001)

관련 논문AI추천